AI, quantum simulation, and synthetic biology are accelerating drug discovery in ways that were impossible just a few years ago - compressing timelines, expanding what’s scientifically feasible, and opening new paths for treating unmet medical needs. As these technologies move from research to real-world impact, regulators, developers, and the public face new questions around evaluation, trust, and access. This panel explores how we can modernize oversight, build confidence in AI-enabled science, and ensure that faster innovation translates into broader patient benefit.
